GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: compound F [WO2021216671A1] | example 5A [US20210330651A1] | ZNc5
Compound class:
Synthetic organic
Comment: ZN-c5 was developed as an orally bioavailable selective estrogen receptor degrader (SERD) [1], for potential to treat breast cancer brain metastases. The core structure of ZN-c5 was used in the design of compounds with improved brain penetration and in vitro and in vivo efficacy, such as compound 5 [PMID: 40393772] [3].
|
|
References |
1. Huang PQ, Hedge SG, Bunker KD, Knight J, Pinchman JR, Unni AK, Sit RK, Zhu S, Hopkins CD, Scott I. (2021)
Preparation of an selective estrogen receptor degrader. Patent number: WO2021216671A1. Assignee: Recurium Ip Holdings, Llc. Priority date: 21/04/2021. Publication date: 28/10/2021. |
2. Huang PQ, Slee DH, Hedge SG, Hopkins CD, Bunker KD, Pinchman JR, Sit RK. (2021)
Estrogen receptor modulators. Patent number: US20210330651A1. Assignee: KALYRA PHARMACEUTICALS, INC.. Priority date: 06/07/2021. Publication date: 28/10/2021. |
3. Zhang G, Huang PQ, Bunker KD, Hegde SG, Ma J, Lee CC, Samatar AA, Unni A, Al-Amin M, Kakarla R. (2025)
Discovery of an Orally Bioavailable and Brain Penetrant Selective Estrogen Receptor Degrader. J Med Chem, 68 (11): 11990-12003. [PMID:40393772] |